| 2025 – 26 : |
Unit-2 Visakhapatnam facility have " *Best Management Award* " by the *Government of Andhra Pradesh on 20th May 2026.
- This achievement reflects the dedication, teamwork, discipline, and continuous efforts of every member of our organization.
- It is a proud moment for all of us and a recognition of our commitment towards operational excellence, employee engagement, innovation, and organizational values.
|
| 2025 – 26 : |
Best API Manufacturing Factory Award" from the Telangana State Government
- Our unwavering commitment towards maintaining the highest safety standards
- Strict adherence to EHS & Quality practices and regulatory compliance
- Continuous employee involvement and safety awareness initiatives
- Teamwork, operational excellence, and responsible manufacturing practices
- The recognition motivates us further to continue our journey towards achieving world-class standards in API manufacturing while ensuring a Safety, Quality and healthy workplace for everyone.
|
| 2024 – 25 : |
- Approved by USFDA in Unit-I
- Received ISO 9001:2015 certification for Unit-I, II, III, IV & V
- Inspected by CFDA in Unit-I, II & III
- PMDA Japan accreditation received for Loperamide HCl in Unit-II
- Approved by USFDA in Unit-III
- PMDA GMP certification received for Intermediate API of Loperamide HCl in Unit-V
|
| 2023 – 24 : |
- Eco Vadis CSR Bronze rating received for Unit-II
- Approved by USFDA in Unit-II
- Approved by ANVISA in Unit-II
- Successfully achieved PMDA certification in Unit-III
- EU-WC renewed for APIs in Unit-III
- Eco Vadis CSR Bronze rating received for Unit-III & Unit-V
- EU-WC grant received from CDSCO for Unit-V
|
| 2022 – 23 : |
- EU-WC received from CDSCO for Unit-II
- Received EDQM certificate for Unit-II
- Successfully achieved ANVISA renewal
- ISO 14001:2015 & ISO 45001:2015 renewed in Unit-III
|
| 2021 – 22 : |
- ISO 14001:2015 & ISO 45001:2018 certified for Unit-I and Unit-II
- EDQM certified Unit-I
- Obtained WHO GMP certification for additional products in Unit-V
- Obtained CEP certificate for Olmesartan Medoxomil in Unit-V
- Process Safety Management Program implemented in Unit-I & II
- Renewal of EU-WC received for Unit-II
- NDA Uganda inspection successfully completed for Unit-II
|
| 2020 – 21 : |
- Total Revenue crossed INR. 11.00 billion
- PMDA Japan accreditation received for Unit-I & II
- EU written confirmation renewed for APIs in Unit-III
- ISO EMS 14001:2015 and ISO 45001:2018 certified for Unit-V
- Obtained WHO GMP certification for Unit-V
- EDQM remote inspection completed in Unit-I
- Eco Vadis CSR Bronze rating received in Unit-II
- Process Safety Management Program introduced in Unit-III
|
| 2019 – 20 : |
- PMDA conducted 2nd surveillance audit for Unit-I
- KFDA inspected Unit-III
- Successfully completed USFDA 2nd surveillance audit for Unit-III
|
| 2018 – 19 : |
- India Ratings upgraded outlook to Positive
- Obtained WHO-GMP certification for Unit-IV
- Successfully completed USFDA 3rd surveillance audit for Unit-I
- Russian GMP inspected Unit-I
- Total Revenue crossed INR. 8.00 billion
|
| 2017 – 18 : |
- EDQM certified Unit-I
- USFDA certified Unit-II and Unit-III
- ISO EMS 14001:2015BS & OHSAS 18001:2007 certified for Unit-III
|
| 2016 – 17 : |
- Turnover crossed INR. 6.00 billion
- India Ratings upgraded long-term rating from "IND A-" to "IND A" with Stable Outlook
- Short-term rating affirmed at "IND A1"
- PMDA certified Unit-I
- WHO (COPP) GMP certificate received for Unit-III
|
| 2015 – 16 : |
- Received status of "Two Star Export House"
- Successfully completed USFDA surveillance audit for Unit-I
- Mexican MOH (COFEPRIS) certified Unit-I & Unit-II
|
| 2014 – 15 : |
- Turnover crossed INR. 5.00 billion
|
| 2013 – 14 : |
- India Ratings upgraded long-term issuer rating from "IND BBB+" to "IND A-" with Stable Outlook
- Short-term rating upgraded from "IND A2+" to "IND A1"
- EU-WC received from CDSCO for Unit-I & Unit-II
|
| 2012 – 13 : |
- Successfully completed USFDA 1st surveillance audit for Unit-I
|
| 2011 – 12 : |
- Turnover crossed INR. 4.00 billion
- Fitch Ratings assigned "BBB+ (Ind)" long-term and "F2+ (Ind)" short-term ratings
- Obtained WHO-GMP certification for Unit-III APIs
|
| 2010 – 11 : |
- Turnover crossed INR. 3.00 billion
- Commenced operations of Unit-III at Jawaharlal Nehru Pharma City, Visakhapatnam
- USFDA approved Unit-I facility
- Mexican MOH (COFEPRIS) certified Unit-I
- KFDA certified Unit-I and Unit-II
|
| 2008 – 09 : |
- Turnover crossed INR. 2.00 billion
- Obtained WHO GMP certification for Unit-II products
|
| 2007 – 08 : |
- Commenced operations of Unit-II at Jawaharlal Nehru Pharma City, Visakhapatnam
|
| 2006 – 07 : |
- Upgraded Unit-I to cGMP standards
|
| 2005 – 06 : |
- Turnover crossed the milestone of INR. 1.00 billion
- Received status of "Star Export House" from Ministry of Commerce & Industry, Govt. of India
- Received Dr. M. Visweswaraya Industrial Award - 2005 for Best Export Performance
- Received "World Quality Commitment International Star Award" – Paris 2005 for Total Quality Management
|
| 2003 – 04 : |
- Obtained WHO GMP certification to all the leading APIs of its Unit-I
- CHEMEXCIL, Mumbai presented the "First Award" for Outstanding Export Performance in Drug & Pharmaceuticals panel for the year 2003
|
| 1997 – 98 : |
- Commenced operations of Unit - I with turnover of INR. 0.02 billion
|
| 1994 – 95 : |
|
